Posters
« Back
The MODEL-AD consortium preclinical testing pipeline: pharmacokinetics and pharmacodynamics of prophylactic treatment with levetiracetam on the 5XFAD mouse model of Alzheimer’s Disease
EP28949
Poster Title: The MODEL-AD consortium preclinical testing pipeline: pharmacokinetics and pharmacodynamics of prophylactic treatment with levetiracetam on the 5XFAD mouse model of Alzheimer’s Disease
Submitted on 14 Aug 2018
Author(s): SJ Sukoff Rizzo1, SK Quinney2, KD Onos1, KJ Keezer1, DR Jones2, AR Masters2, IF Metzger2, JA Meyer2, J Peters2, SC Persohn2, BR McCarthy2, AA Riley2, M Sasner1, G Howell1, H Williams1, AJ Oblak2, BL Lamb2, and PR Territo2
Affiliations: 1The Jackson Laboratory, Bar Harbor, Maine USA; 2Indiana University School of Medicine, Indianapolis, Indiana USA
This poster was presented at AAIC 2018
Poster Views: 502
View poster »


Poster Information
Abstract: The preclinical testing core (PTC) of the Model Organism Development for Late Onset Alzheimer’s Disease (MODEL-AD) consortium has established a streamlined preclinical drug testing strategy with go/no-go decision points that allow critical and unbiased assessments of potential therapeutic agents. The goals of the PTC are to develop a testing strategy that maximizes the therapeutic potential of all drug candidates by initiating the dosing strategy prior to the onset of disease relevant biomarker readouts.
The PTC strategy includes a primary screen to determine: 1) drug formulation; 2) drug stability; and 3) in vivo pharmacokinetics and target tissue concentrations in models at disease-relevant ages. A secondary screen evaluates target engagement and disease modifying activity utilizing non-invasive PET/MRI as a pharmacodynamic (PD) readout matched to known disease pathology in the model. Compounds demonstrating positive PD effects in the secondary screen are further interrogated via a tertiary screen of functional assays that assess the compounds ability to normalize a disease-related phenotype in cognition and neurophysiological tests. For the present studies, we selected levetiracetam (LEV), a compound currently in clinical trials for the treatment of cognitive impairment associated with AD, for testing in 5XFAD mice.
Summary: The PTC pipeline for MODEL-AD using levetiracetam as a pipeline testing compound.Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


Functional Assay of Neural Activity with Cell-Based Neural Culture Models and Microelectrode Array Technology for Proconvulsant Risk Assessment in the Neutox Pilot Study
Millard, D.C.; Hayes, H.B.; Nicolini, A.M.; Arrowood, C.A.; Clements, M;

Multiplex miRNA Profiling for Biomarker Discovery and Verification Studies Using the FirePlex® Platform
M. Tackett, B. Heinrich, I. Diwan, G. Tejada, C. Rafferty, E. Atabakhsh, and D. Pregibon

Accelerating high-throughput screening with FirePlex®-HT:An automatable, multiplex immunoassay using FirePlex® Particle Technology
A. Perea, B. Heinrich, W. Austin, C. Rafferty, M. Camilleri, L. To, E. Atabakhsh, and D. Pregibon

MOSQUITO COIL SMOKE DEPLETES IRON (Fe) CONCENTRATION IN CEREBRUM OF WISTAR RATS
MAHMOOD USMAN, SADEEQ A. ADAMU, SHERIF AHMAD-ISAH, MUHAMMAD M. MUBASSHIR, IBRAHIM S. ELLADAN, AFFAN USMAN, ADEBAYO A. BURAIMOH

riboPOOL: Affordable Custom/Ribosomal RNA Depletion Against Any Species for RNA-Seq
Catherine Goh1, Andrew Walsh1, Michaela Beitzinger1, Jonas Bertram1, Kristina Döring3, Sascha Dietrich3, Iana Kim4, Stefan Kotschote2, Claus Kuhn4, Konrad Förstner3, Michael Bonin2, Stefan Hannus1, Michael Hannus1